Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits

Tijana Drobnjak, Hamutal Meiri, Maurizio Mandalá, Berthold Huppertz, Sveinbjorn Gizurarson

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia. Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model. Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p < 0.01). PP13 elimination half-life was also found to be different between the groups (p < 0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%. Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated.
Original languageEnglish
Pages (from-to)1977-1983
JournalDrug Design, Development and Therapy
Publication statusPublished - Jul 2018

Other keywords

  • Pharmacology
  • Drug Discovery
  • Pharmaceutical Science
  • Lyfjafræði
  • Lyfjaefnafræði
  • Lyfhrifafræði


Dive into the research topics of 'Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits'. Together they form a unique fingerprint.

Cite this